Physician profile
James S Stepanski
NPI 1669462974
$6,057.41
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,574 · 2020: $1,271 · 2021: $1,844 · 2022: $1,286 · 2023: $61.26 · 2024: $21.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $82.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $82.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $841.83 | 2019-2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.97 | 2019-2022 | |
| Amarin Pharma, INC. | $480.23 | 2019-2022 | |
| Abbvie INC. | $474.44 | 2019-2022 | |
| Lilly USA, LLC | $409.75 | 2019-2022 | |
| Astellas Pharma US INC | $341.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $316.21 | 2019-2022 | |
| Pfizer INC. | $306.92 | 2019-2023 | |
| Novo Nordisk INC | $247.96 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $209.54 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.03 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $164.78 | 2020-2022 | |
| Allergan, INC. | $126.49 | 2019-2020 | |
| Amgen INC. | $109.36 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $106.71 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $99.50 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $94.33 | 2022 | |
| Glaxosmithkline, LLC. | $93.81 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $82.41 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.57 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $72.48 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $65.89 | 2019-2020 | |
| Horizon Therapeutics Plc | $63.52 | 2019-2022 | |
| Adlon Therapeutics L.P. | $61.20 | 2020-2021 | |
| Abbott Laboratories | $57.94 | 2022-2024 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $53.36 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $46.95 | 2019-2021 | |
| Sanofi Pasteur INC. | $33.32 | 2019 | |
| Ibsa Pharma INC. | $26.51 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.93 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.58 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stepanski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.